AU754124B2 - Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P - Google Patents

Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P Download PDF

Info

Publication number
AU754124B2
AU754124B2 AU54229/99A AU5422999A AU754124B2 AU 754124 B2 AU754124 B2 AU 754124B2 AU 54229/99 A AU54229/99 A AU 54229/99A AU 5422999 A AU5422999 A AU 5422999A AU 754124 B2 AU754124 B2 AU 754124B2
Authority
AU
Australia
Prior art keywords
methyl
imidazol
pyrazol
ethoxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54229/99A
Other languages
English (en)
Other versions
AU5422999A (en
Inventor
Jordi Frigola-Constansa
Ramon Merce-Vidal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of AU5422999A publication Critical patent/AU5422999A/en
Application granted granted Critical
Publication of AU754124B2 publication Critical patent/AU754124B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU54229/99A 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P Ceased AU754124B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES009801708A ES2150378B1 (es) 1998-08-07 1998-08-07 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p.
ES9801708 1998-08-07
PCT/ES1999/000255 WO2000007542A2 (es) 1998-08-07 1999-08-05 Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p

Publications (2)

Publication Number Publication Date
AU5422999A AU5422999A (en) 2000-02-28
AU754124B2 true AU754124B2 (en) 2002-11-07

Family

ID=8304839

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54229/99A Ceased AU754124B2 (en) 1998-08-07 1999-08-05 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P

Country Status (26)

Country Link
US (1) US6518295B1 (https=)
EP (1) EP1103243B1 (https=)
JP (1) JP2002522359A (https=)
KR (1) KR100558506B1 (https=)
CN (1) CN1151789C (https=)
AR (1) AR019999A1 (https=)
AT (1) ATE257379T1 (https=)
AU (1) AU754124B2 (https=)
BR (1) BR9912807A (https=)
CA (1) CA2339661C (https=)
CO (1) CO5080747A1 (https=)
CZ (1) CZ292065B6 (https=)
DE (1) DE69914085T8 (https=)
DK (1) DK1103243T3 (https=)
ES (2) ES2150378B1 (https=)
HU (1) HUP0105428A3 (https=)
IL (1) IL141295A0 (https=)
NO (1) NO20010634L (https=)
NZ (1) NZ509645A (https=)
PL (1) PL193802B1 (https=)
PT (1) PT1103243E (https=)
RU (1) RU2223116C2 (https=)
TR (1) TR200100378T2 (https=)
TW (1) TW445259B (https=)
WO (1) WO2000007542A2 (https=)
ZA (1) ZA200100867B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174756B2 (es) * 2001-04-06 2003-11-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
ES2180449B1 (es) * 2001-07-06 2004-01-16 Esteve Labor Dr Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria.
DE10335566A1 (de) * 2003-07-31 2005-02-24 Grünenthal GmbH Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
WO2006010627A1 (en) * 2004-07-30 2006-02-02 Laboratorios Del Dr. Esteve, S.A. Aryl (or heteroaryl) azolylcarbinols
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
ES2286920B1 (es) * 2005-02-15 2008-08-16 Laboratorios Del Dr. Esteve, S.A. Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia.
WO2006087147A2 (en) * 2005-02-15 2006-08-24 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1695704A1 (en) * 2005-02-28 2006-08-30 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia
EP1690537A1 (en) * 2005-02-15 2006-08-16 Laboratorios Del Dr. Esteve, S.A. Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia
CA2637312A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of substituted 2-imidazole of imidazoline derivatives
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
RU2009112496A (ru) 2006-10-19 2010-11-27 Ф. Хоффманн-Ля Рош Аг (Ch) Аминометил-4-имидазолы
CA2668454A1 (en) 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles
JP2010510184A (ja) 2006-11-16 2010-04-02 エフ．ホフマン−ラ ロシュ アーゲー 置換４−イミダゾール類
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
CA2672617A1 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag Novel 2-imidazoles as ligands for trace amine associated receptors (taar)
CN101600700B (zh) 2007-02-02 2013-08-21 弗·哈夫曼-拉罗切有限公司 作为taar1配体用于cns病症的新的2-氨基噁唑啉
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
CN101687812A (zh) 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
CA2691704A1 (en) 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
CA2694362A1 (en) 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
JP5341084B2 (ja) 2007-08-03 2013-11-13 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体
US8242153B2 (en) 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
US20100291151A1 (en) * 2009-04-21 2010-11-18 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
CN108713019B (zh) 2016-03-17 2021-06-15 豪夫迈·罗氏有限公司 具有作为taar的激动剂的活性的5-乙基-4-甲基-吡唑-3-甲酰胺衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613720B1 (fr) * 1987-04-10 1990-01-19 Esteve Labor Dr Derives d'aryl-heteroaryl carbinols avec activite analgesique
FR2681322B1 (fr) * 1991-09-12 1993-12-17 Laboratorios Dr Esteve Sa Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments .
CA2154116A1 (en) * 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists
FR2742147B1 (fr) * 1995-12-06 1998-02-27 Esteve Labor Dr Procede de separation de carbinols
CA2273810A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating major depressive disorders
JP2001504848A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 重症不安障害の治療のためのｎｋ−１受容体拮抗薬の使用
EP0942735A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating schizophrenic disorders
CA2273853A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
US6518295B1 (en) 2003-02-11
KR100558506B1 (ko) 2006-03-07
CA2339661A1 (en) 2000-02-17
HUP0105428A2 (hu) 2002-05-29
CZ2001412A3 (cs) 2001-08-15
ES2150378B1 (es) 2001-07-01
DK1103243T3 (da) 2004-05-03
HUP0105428A3 (en) 2003-01-28
ATE257379T1 (de) 2004-01-15
TW445259B (en) 2001-07-11
WO2000007542A3 (es) 2000-05-11
NO20010634L (no) 2001-04-06
CZ292065B6 (cs) 2003-07-16
EP1103243B1 (en) 2004-01-07
ES2213380T3 (es) 2004-08-16
TR200100378T2 (tr) 2001-06-21
NO20010634D0 (no) 2001-02-06
WO2000007542A2 (es) 2000-02-17
CA2339661C (en) 2006-10-17
CO5080747A1 (es) 2001-09-25
ZA200100867B (en) 2001-08-16
PL193802B1 (pl) 2007-03-30
ES2150378A1 (es) 2000-11-16
RU2223116C2 (ru) 2004-02-10
KR20010079616A (ko) 2001-08-22
JP2002522359A (ja) 2002-07-23
AU5422999A (en) 2000-02-28
EP1103243A2 (en) 2001-05-30
CN1151789C (zh) 2004-06-02
IL141295A0 (en) 2002-12-01
CN1317966A (zh) 2001-10-17
PL346221A1 (en) 2002-01-28
BR9912807A (pt) 2001-10-16
NZ509645A (en) 2003-01-31
DE69914085T2 (de) 2004-11-25
PT1103243E (pt) 2004-05-31
DE69914085D1 (de) 2004-02-12
AR019999A1 (es) 2002-03-27
DE69914085T8 (de) 2005-04-21

Similar Documents

Publication Publication Date Title
AU754124B2 (en) Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P
JP5966014B2 (ja) 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用
RU2001106644A (ru) Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p
CN102652135A (zh) 脂肪酸酰胺水解酶的含氮杂环抑制剂
DK3027183T3 (en) SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT
ES2694375T3 (es) Composiciones para el tratamiento de la hipertensión y/o de la fibrosis
JPH04290823A (ja) 心臓および血管の肥大および過形成の治療剤
JP2017014224A (ja) 帯状疱疹関連痛の急性期疼痛の予防又は治療剤
AU2006321907A1 (en) Use of a CB1 antagonist for treating negative symptoms of schizophrenia
EP1687001A2 (en) Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
WO2016096125A1 (en) Use of sigma receptor ligands in osteoarthritis
EP1746986A1 (en) Active substance combination comprising a carbinol combined to at least an nsaid
ITRM970586A1 (it) Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
Pinna et al. Modulation of glycine transporters as a novel therapeutic strategy in neuropsychiatry
CN108601784A (zh) 药物
DK2888259T3 (en) Diazepinone derivatives suitable for the treatment of fragile X syndrome, Parkinson's or reflux disease
CN102906085A (zh) 2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基-磺酰胺衍生物
CA2332711A1 (en) Use of derivatives of aryl(or heteroaryl)azolylcarbinols in the manufacture of a medicament for the treatment of neurogenic inflammation
JP2002529406A (ja) ＧＡＢＡＡα５逆活性薬と、ＣＯＸ−２阻害剤、ＮＳＡＩＤ、エストロゲン、又はビタミンＥとの組合わせ
MXPA01001438A (en) Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)